

Amendments to the Claims:

Claims 1-22 (Cancelled)

23. (Currently Amended) A cell having a transferred fusion protein, said fusion protein transferred by:

coating the surface of said cell with a first protein, wherein said first protein is a lipidated protein; and

contacting said cell with a second protein, wherein said second protein is said fusion protein and is comprised of a first domain having affinity for said first protein and a second domain having *trans*-signaling and/or adhesion function having a lipidated protein incorporated into the cell membrane, said lipidated protein having bound thereto a fusion protein, said fusion protein comprising a first domain and a second domain, said second domain having a *trans*-signaling and/or adhesion function.

Claims 24-36 (Withdrawn)

Claims 37-50 (Cancelled)

51. (Currently Amended) The cell of Claim 23, wherein said first lipidated protein is selected from the group consisting of lipidated protein A and lipidated protein G.

52. (Currently Amended) The cell of Claim 23, wherein said first lipidated protein is palmitated protein A.

53. (Currently Amended) The cell of Claim 23, wherein said first domain is attached at the amino terminus of said second fusion protein.

54. (Currently Amended) The cell of Claim 23, wherein said first domain is attached at the carboxyl terminus of said second fusion protein.

55. (Previously added) The cell of Claim 23, wherein said second domain encodes a type I membrane protein.

56. (Previously added) The cell of Claim 23, wherein said second domain encodes a type II membrane protein.

57. **(Previously added)** The cell of Claim 23, wherein said second domain encodes a costimulator.

58. **(Previously added)** The cell of Claim 23, wherein said second domain encodes an inhibitor.

59. **(Previously added)** The cell of Claim 57, wherein said costimulator is selected from the group consisting of B7-1, B7-2, ICAM-1, ICAM-2, ICAM-3, CD48, LFA-3, 4-1BB ligand, CD30 ligand, CD40 ligand, and heat stable antigen.

60. **(Currently Amended)** The cell of Claim 59, wherein said second fusion protein is B7-1-Fc γ I.

61. **(Previously added)** The cell of Claim 58, wherein said inhibitor is selected from the group consisting of CD8, Fas ligand and a single chain Fv derivative of immunoglobulin.